Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
PAR FY 1990 SALES DOWN 52% TO $49 MIL. WITH LOSS OF $14.8 MIL.; QUAD REGULATORY AUDIT IS IN "EARLY STAGE" BUT ORAL SOLID LINE IS 95% BACK ON LINE
Dec 03 1990
•
By
The Pink Sheet
More from Archive
More from Pink Sheet